These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23247129)

  • 1. Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model.
    Chen L; Fan C; Zhang Y; Bakri M; Dong H; Morisseau C; Maddipati KR; Luo P; Wang CY; Hammock BD; Wang MH
    Prostaglandins Other Lipid Mediat; 2013; 104-105():42-8. PubMed ID: 23247129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis.
    Luo P; Chang HH; Zhou Y; Zhang S; Hwang SH; Morisseau C; Wang CY; Inscho EW; Hammock BD; Wang MH
    J Pharmacol Exp Ther; 2010 Aug; 334(2):430-8. PubMed ID: 20439437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus.
    Jouihan SA; Zuloaga KL; Zhang W; Shangraw RE; Krasnow SM; Marks DL; Alkayed NJ
    J Cereb Blood Flow Metab; 2013 Oct; 33(10):1650-6. PubMed ID: 23899929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.
    Chen G; Xu R; Wang Y; Wang P; Zhao G; Xu X; Gruzdev A; Zeldin DC; Wang DW
    Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E563-75. PubMed ID: 22739108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.
    Elmarakby AA; Faulkner J; Pye C; Rouch K; Alhashim A; Maddipati KR; Baban B
    Clin Sci (Lond); 2013 Oct; 125(7):349-59. PubMed ID: 23611540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.
    Roche C; Besnier M; Cassel R; Harouki N; Coquerel D; Guerrot D; Nicol L; Loizon E; Remy-Jouet I; Morisseau C; Mulder P; Ouvrard-Pascaud A; Madec AM; Richard V; Bellien J
    Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1020-9. PubMed ID: 25724490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance.
    Luria A; Bettaieb A; Xi Y; Shieh GJ; Liu HC; Inoue H; Tsai HJ; Imig JD; Haj FG; Hammock BD
    Proc Natl Acad Sci U S A; 2011 May; 108(22):9038-43. PubMed ID: 21571638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of protection by soluble epoxide hydrolase inhibition in type 2 diabetic stroke.
    Zuloaga KL; Krasnow SM; Zhu X; Zhang W; Jouihan SA; Shangraw RE; Alkayed NJ; Marks DL
    PLoS One; 2014; 9(5):e97529. PubMed ID: 24824753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meloxicam fails to augment the reno-protective effects of soluble epoxide hydrolase inhibition in streptozotocin-induced diabetic rats via increased 20-HETE levels.
    Katary MM; Pye C; Elmarakby AA
    Prostaglandins Other Lipid Mediat; 2017 Sep; 132():3-11. PubMed ID: 27596333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice.
    Roche C; Guerrot D; Harouki N; Duflot T; Besnier M; Rémy-Jouet I; Renet S; Dumesnil A; Lejeune A; Morisseau C; Richard V; Bellien J
    Prostaglandins Other Lipid Mediat; 2015 Jul; 120():148-54. PubMed ID: 26022136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches.
    Li N; Liu JY; Timofeyev V; Qiu H; Hwang SH; Tuteja D; Lu L; Yang J; Mochida H; Low R; Hammock BD; Chiamvimonvat N
    J Mol Cell Cardiol; 2009 Dec; 47(6):835-45. PubMed ID: 19716829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis.
    Shen L; Peng H; Peng R; Fan Q; Zhao S; Xu D; Morisseau C; Chiamvimonvat N; Hammock BD
    Atherosclerosis; 2015 Apr; 239(2):557-65. PubMed ID: 25733327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EETs/sEH in diabetes and obesity-induced cardiovascular diseases.
    Huang H; Weng J; Wang MH
    Prostaglandins Other Lipid Mediat; 2016 Sep; 125():80-9. PubMed ID: 27184755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of diabetes on male sexual function in streptozotocin-induced diabetic rats: Protective role of soluble epoxide hydrolase inhibitor.
    Minaz N; Razdan R; Hammock BD; Mujwar S; Goswami SK
    Biomed Pharmacother; 2019 Jul; 115():108897. PubMed ID: 31102913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice.
    Zhang W; Yang AL; Liao J; Li H; Dong H; Chung YT; Bai H; Matkowskyj KA; Hammock BD; Yang GY
    Dig Dis Sci; 2012 Oct; 57(10):2580-91. PubMed ID: 22588244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of soluble epoxide hydrolase inhibition and CYP2J2 overexpression on postischemic cardiac function in aged mice.
    Chaudhary KR; Zordoky BN; Edin ML; Alsaleh N; El-Kadi AO; Zeldin DC; Seubert JM
    Prostaglandins Other Lipid Mediat; 2013; 104-105():8-17. PubMed ID: 22922020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure.
    Sun D; Cuevas AJ; Gotlinger K; Hwang SH; Hammock BD; Schwartzman ML; Huang A
    Am J Physiol Heart Circ Physiol; 2014 Apr; 306(8):H1146-53. PubMed ID: 24561863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.
    Guglielmino K; Jackson K; Harris TR; Vu V; Dong H; Dutrow G; Evans JE; Graham J; Cummings BP; Havel PJ; Chiamvimonvat N; Despa S; Hammock BD; Despa F
    Am J Physiol Heart Circ Physiol; 2012 Oct; 303(7):H853-62. PubMed ID: 22865388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.
    Revermann M; Barbosa-Sicard E; Dony E; Schermuly RT; Morisseau C; Geisslinger G; Fleming I; Hammock BD; Brandes RP
    J Hypertens; 2009 Feb; 27(2):322-31. PubMed ID: 19226702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced coronary reactive hyperemia in mice was reversed by the soluble epoxide hydrolase inhibitor (t-AUCB): Role of adenosine A
    Hanif A; Edin ML; Zeldin DC; Morisseau C; Falck JR; Ledent C; Tilley SL; Nayeem MA
    Prostaglandins Other Lipid Mediat; 2017 Jul; 131():83-95. PubMed ID: 28890385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.